<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01484054</url>
  </required_header>
  <id_info>
    <org_study_id>CR-005128</org_study_id>
    <nct_id>NCT01484054</nct_id>
  </id_info>
  <brief_title>Dispensing Evaluation of Subjective Comfort, Vision, and Handling of a New Lens Compared to a Marketed Lens</brief_title>
  <official_title>Dispensing Evaluation of Lens Comfort and Subjective Vision of an Etafilcon A With Print and PVP Lens for Dark Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the performance of a new contact lens to a marketed contact lens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Reported Overall Quality of Lens Vision Using the Contact Lens User Evaluation (CLUE) Questionnaire</measure>
    <time_frame>After 7 to 9 days of lens wear</time_frame>
    <description>The overall quality of lens vision was assessed using the CLUE questionnaire after 7-9 days of follow-up. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range from 0-120.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject Reported Overall Lens Comfort Using the Contact Lens User Evaluation (CLUE) Questionnaire</measure>
    <time_frame>After 7 to 9 days of lens wear</time_frame>
    <description>The overall lens comfort was assessed using the CLUE questionnaire after 7-9 days of follow-up.The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject Reported Overall Lens Handling Using the Contact Lens User Evaluation (CLUE) Questionnaire</measure>
    <time_frame>After 7 to 9 days of lens wear</time_frame>
    <description>The overall lens handling was assessed using the CLUE questionnaire after 7-9 days of follow-up. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Refractive Ametropia</condition>
  <arm_group>
    <arm_group_label>EAPVPDE/EADE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>etafilcon A with embedded print and PVP lens for dark eyes worn daily during the first period of 7-9 days, then etafilcon A control lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EADE/EAPVPDE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>etafilcon A control lens worn daily during the first period of 7-9 days, then etafilcon A with embedded print and PVP for dark eyes lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A with print and PVP for dark eyes (EAPVPDE)</intervention_name>
    <description>A daily disposable contact lens</description>
    <arm_group_label>EAPVPDE/EADE</arm_group_label>
    <arm_group_label>EADE/EAPVPDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A control lens (EADE)</intervention_name>
    <description>A marketed daily disposable contact lens</description>
    <arm_group_label>EAPVPDE/EADE</arm_group_label>
    <arm_group_label>EADE/EAPVPDE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must be a healthy adult at least 18 years of age and no more than 34 years
             of age.

          -  The subjects must be female, dark eye Caucasian, Non-Hispanic habitual soft contact
             lens wearer (both eyes).

          -  The subject rated the Concept Statement positively (i.e., a rating of 4 or 5). If not
             the subject is not eligible to participate.

          -  The subject must have no known ocular or systemic allergies that might interfere with
             contact lens wear.

          -  The subject must have no known systemic disease, or need for medication, which might
             interfere with contact lens wear.

          -  The subject's optimal vertexed spherical equivalent distance correction must be
             between-1.00 and -4.00D.

          -  Any cylinder power must be:&lt;=0.75D.

          -  The subject must have visual acuity best correctable to 20/25 or better for each eye.

          -  The subject must have normal eyes (no ocular medications or ocular infection of any
             type).

          -  The subject must read and sign the Statement of Informed Consent.

          -  The subject must appear able and willing to adhere to the instructions set forth in
             this clinical protocol.

        Exclusion Criteria:

          -  Ocular or systemic allergies or disease which might interfere with contact lens wear.

          -  Systemic disease, autoimmune disease, or use of medication which might interfere with
             contact lens wear.

          -  Clinically significant (grade 3 or worse) corneal edema, corneal neovascularization,
             corneal staining, or any other abnormalities of the cornea which would contraindicate
             contact lens wear.

          -  Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which
             might interfere with contact lens wear.

          -  Any ocular infection.

          -  Any corneal distortion resulting from previous hard or rigid gas permeable contact
             lens wear.

          -  Any color deficiencies (color blindness) - to the best of the subject's knowledge.

          -  Pregnancy or lactation.

          -  Diabetes.

          -  Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease
             (e.g. HIV).

          -  Habitual contact lens type is toric, multifocal, or is worn as extended wear.

          -  Subject presents with one dark iris color and one light iris color

          -  Subject has heterochromia iridis (a difference in color between parts of one iris)

          -  The subject is an employee or family member of the clinical study site.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Bloomfield</city>
        <state>Connecticut</state>
        <zip>06002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jamestown</city>
        <state>New York</state>
        <zip>14750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moon Township</city>
        <state>Pennsylvania</state>
        <zip>15108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2011</study_first_posted>
  <results_first_submitted>August 30, 2013</results_first_submitted>
  <results_first_submitted_qc>December 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2014</results_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of those 103 enrolled subjects, 3 subjects did not receive the study article.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EAPVPDE/EADE</title>
          <description>etafilcon A with embedded print and PVP for dark eyes lens worn daily during the first period of 7-9 days then etafilcon A control lens worn daily during the second period of 7-9 days with a 1-3 day of wash-out time between 2 periods.</description>
        </group>
        <group group_id="P2">
          <title>EADE/EAPVPDE</title>
          <description>etafilcon A control lens worn daily during the first period of 7-9 days then etafilcon A with embedded print and PVP for dark eyes lens worn daily during the second period of 7-9 days with a 1-3 day of wash-out time between 2 periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline summary was conducted on all enrolled subjects who received study lenses.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All enrolled subjects who received study lenses.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.07" spread="4.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Reported Overall Quality of Lens Vision Using the Contact Lens User Evaluation (CLUE) Questionnaire</title>
        <description>The overall quality of lens vision was assessed using the CLUE questionnaire after 7-9 days of follow-up. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range from 0-120.</description>
        <time_frame>After 7 to 9 days of lens wear</time_frame>
        <population>Analysis was conducted on subjects who successfully complete the study without a protocol deviation affecting at least one primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>EAPVPDE</title>
            <description>A daily disposable contact lens.</description>
          </group>
          <group group_id="O2">
            <title>EADE</title>
            <description>A marketed daily disposable contact lens</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reported Overall Quality of Lens Vision Using the Contact Lens User Evaluation (CLUE) Questionnaire</title>
          <description>The overall quality of lens vision was assessed using the CLUE questionnaire after 7-9 days of follow-up. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range from 0-120.</description>
          <population>Analysis was conducted on subjects who successfully complete the study without a protocol deviation affecting at least one primary endpoint.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.06" spread="2.538" lower_limit="48.56" upper_limit="59.57"/>
                    <measurement group_id="O2" value="53.06" spread="2.537" lower_limit="47.56" upper_limit="58.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis is that etafilcon A with PVP lenses is non-inferior to etafilcon A control lenses for the Overall Quality of Lens Vision at 7-9 days of follow-up.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -5 points(CLUE) was used.</non_inferiority_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.117</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.20</ci_lower_limit>
            <ci_upper_limit>5.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject Reported Overall Lens Comfort Using the Contact Lens User Evaluation (CLUE) Questionnaire</title>
        <description>The overall lens comfort was assessed using the CLUE questionnaire after 7-9 days of follow-up.The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>After 7 to 9 days of lens wear</time_frame>
        <population>Analysis was conducted on subjects who successfully complete the study without a protocol deviation affecting at least one primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>EAPVPDE</title>
            <description>A daily disposable contact lens</description>
          </group>
          <group group_id="O2">
            <title>EADE</title>
            <description>A marketed daily disposable contact lens</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reported Overall Lens Comfort Using the Contact Lens User Evaluation (CLUE) Questionnaire</title>
          <description>The overall lens comfort was assessed using the CLUE questionnaire after 7-9 days of follow-up.The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>Analysis was conducted on subjects who successfully complete the study without a protocol deviation affecting at least one primary endpoint.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.61" spread="2.201" lower_limit="49.27" upper_limit="57.95"/>
                    <measurement group_id="O2" value="48.91" spread="2.197" lower_limit="44.58" upper_limit="53.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis is that etafilcon A with PVP lenses is non-inferior to etafilcon A control lenses for the Overall Lens Comfort at 7-9 days of follow-up.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -5 points(CLUE) was used.</non_inferiority_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>4.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.772</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>10.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject Reported Overall Lens Handling Using the Contact Lens User Evaluation (CLUE) Questionnaire</title>
        <description>The overall lens handling was assessed using the CLUE questionnaire after 7-9 days of follow-up. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>After 7 to 9 days of lens wear</time_frame>
        <population>Analysis was conducted on subjects who successfully complete the study without a protocol deviation affecting at least one primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>EAPVPDE</title>
            <description>A daily disposable contact lens</description>
          </group>
          <group group_id="O2">
            <title>EADE</title>
            <description>A marketed daily disposable contact lens</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reported Overall Lens Handling Using the Contact Lens User Evaluation (CLUE) Questionnaire</title>
          <description>The overall lens handling was assessed using the CLUE questionnaire after 7-9 days of follow-up. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>Analysis was conducted on subjects who successfully complete the study without a protocol deviation affecting at least one primary endpoint.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.21" spread="1.847" lower_limit="57.56" upper_limit="64.86"/>
                    <measurement group_id="O2" value="51.77" spread="1.842" lower_limit="48.12" upper_limit="55.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ho: The test lens is non-inferior to the active comparator lens for Handling at 7-9 days follow-up.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -5 points(CLUE) was used.</non_inferiority_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>9.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.829</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.81</ci_lower_limit>
            <ci_upper_limit>13.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded when the subjects were exposed to the Investigational lenses.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EAPVPDE</title>
          <description>etafilcon A material incorporating PVP in the blister packaging solution.</description>
        </group>
        <group group_id="E2">
          <title>EADE</title>
          <description>etafilcon a existing, daily disposable contact lens.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Mayers, OD, FAAO</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care</organization>
      <phone>904-443-3252</phone>
      <email>mmayers@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

